Shedir Pharma Group S.p.A.

SHE

IT0005379620

Pharmaceuticals

Market Closed - Borsa Italiana Other stock markets 16:44:59 20/05/2024 BST			5-day change	1st Jan Change
3.68 ^EUR	-1.08%		+1.10%	-18.58%

04-02	Shedir Pharma, into 2023 with rising revenues; profit down single digits	AN
03-29	Shedir Pharma Group S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Shedir Pharma Group S.P.A. Reports Earnings Results for the Half Year Ended June 30, 2021

September 28, 2021

Shedir Pharma Group S.P.A. Announced earnings results for the half year ended June 30, 2021. For the half year, the company announced total revenue was EUR 19.034 million compared to EUR 19.218 million a year ago. Operating income was EUR 1.053 million compared to EUR 1.828 million a year ago. Net income was EUR 681,000 compared to EUR 1.168 million a year ago.

Latest news about Shedir Pharma Group S.p.A.

Shedir Pharma, into 2023 with rising revenues; profit down single digits	04-02	AN
Shedir Pharma Group S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Shedir Pharma increases profit and revenues in the first half by double digits	29/09/23	AN
Shedir Pharma Group S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2023	28/09/23	CI
Shedir Pharma has purchased 4,500 of its own ordinary shares	23/05/23	AN
Shedir Pharma's share buybacks continue	16/05/23	AN
Shedir Pharma Group has purchased 7,500 of its own shares	02/05/23	AN
Shedir Pharma's share buybacks continue	24/04/23	AN
Milan up; Chinese bank does not touch rates	20/04/23	AN
Milan rises above 27,900; MPS bullish	19/04/23	AN
Indexes weak; TIM down after network bids	19/04/23	AN
Stock markets down ahead of Eurozone inflation	19/04/23	AN
Flat start expected in Europe, focus on results	19/04/23	AN
Milan pink jersey led by banks	18/04/23	AN
Shedir Pharma revenues rise to double digits in first quarter	18/04/23	AN
Shedir Pharma has purchased 4,000 shares of its own common stock	18/04/23	AN
ITALY GROWTH WINNERS & LOSERS: Shedir Pharma on top; Il Fatto down	18/04/23	AN
Shedir Pharma Group S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2022	12/04/23	CI
Shedir Pharma raises dividend after a 2022 closed with growth	31/03/23	AN
Shedir Pharma Group S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2022	28/09/22	CI
Shedir Pharma Group S.p.A. commences an Equity Buyback Plan, under the authorization approved on April 29, 2022.	10/07/22	CI
Shedir Pharma Group S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2021	28/03/22	CI
Shedir Pharma Group S.P.A. Reports Earnings Results for the Half Year Ended June 30, 2021	28/09/21	CI
Certain Shares of Shedir Pharma Group S.p.A. are subject to a Lock-Up Agreement Ending on 24-JUL-2021.	23/07/21	CI
Shedir Pharma Group S.P.A. Reports Earnings Results for the Full Year Ended December 31, 2020	28/03/21	CI

Chart Shedir Pharma Group S.p.A.

Duration

Period

More charts

Company Profile

Shedir Pharma Srl is an Italy-based pharmaceutical company specialized in nutraceuticals, cosmetics and medical devices. The Company markets its products in different forms and under the brand lines Shedir Farmaceutici, Deimos Farmaceutici, Phobos Farmaceutici, Menkar Farmaceutici and Greenplanet Divisione Farmaceutica. Its products cover a wide range of therapeutics areas, such as cardiovascular, dermatology, neurology, urology, gynecology and dental health, among others.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.72 EUR

Average target price

8.08 EUR

Spread / Average Target

+117.20%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHEDIR PHARMA GROUP S.P.A.	-18.58%	45.95M
ELI LILLY AND COMPANY	+34.44%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-2.77%	372B
MERCK & CO., INC.	+20.61%	332B
ABBVIE INC.	+6.69%	294B
ASTRAZENECA PLC	+14.11%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.93%	168B

Other Pharmaceuticals